中国新药崛起是创新体系的不断迭代升级,也是强大产业基建的成功。BD新王诞生Guide View2025年10月22日,信达生物与武田制药达成潜在总金额最高可达114亿美元的授权交易,首付款高达12亿美元,刷新了国内药企对外合作新纪录,BD新王诞生。合作覆盖3款核心在研管线,具体详见下图。其中,IBI363是王炸,为进度最快、数据最好的PD-1/IL-2,BIC+FIC,定位post-PD-1市场,...
Source Link中国新药崛起是创新体系的不断迭代升级,也是强大产业基建的成功。BD新王诞生Guide View2025年10月22日,信达生物与武田制药达成潜在总金额最高可达114亿美元的授权交易,首付款高达12亿美元,刷新了国内药企对外合作新纪录,BD新王诞生。合作覆盖3款核心在研管线,具体详见下图。其中,IBI363是王炸,为进度最快、数据最好的PD-1/IL-2,BIC+FIC,定位post-PD-1市场,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.